Collaborative Drug

OCTOBER 7, 2024

Insights from Structure Activity Relationship Analyses Help Optimize Your Research Structure Activity Relationship (SAR) is among the most important results that your screening data contains. CDD Vault is affordable to academic laboratories, research foundations, and small companies.

FDA Approval 264

FDA Approval Laboratories FDA Research 264

Advarra

JULY 26, 2022

As such, we are seeing an uptick in research examining the therapeutic effects of cannabis and its constituents. with 37 states approving medicinal use and 18 approving recreationally. While there isn’t a significant amount of research on cannabidiol (CBD), it’s easily accessible in the U.S. Funding Research on Cannabis.

Regulations 97

Regulations Research FDA FDA Approval 97

Advarra

JULY 5, 2022

Individuals invest a great deal to participate in clinical research, undertaking risks and burdens, while giving of their time and energies to advance scientific knowledge and the public good. Aggregate and Individual Research Results. Reasons Supporting Return of Individual Research Results.

Research 97

Research FDA Approval FDA Packaging 97

The Pharma Data

JUNE 2, 2023

Food and Drug Administration (FDA) for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. In the U.S., For the U.S.

FDA Approval 52

FDA Approval FDA Therapies Treatment 52

Broad Institute

OCTOBER 11, 2023

Manguso, who’d recently graduated from college and was conducting research at the University of Copenhagen as a Fulbright scholar, moved back to the Boston area to be with his mother as she underwent treatment. They are used to treat cancers including melanoma and non-small cell lung cancer, but work only for a small fraction of patients.

Research 137

Research Immune Response Clinical Trials Therapies 137

Broad Institute

MAY 16, 2024

But FDA-approved forms of the most commonly used vehicle for packaging and delivering these therapies to target cells, adeno-associated viruses (AAVs), aren’t able to efficiently cross the blood-brain barrier at high levels and deliver therapeutic cargo. Several of these therapies have shown evidence of reaching the brain in humans.

Therapies 137

Therapies FDA Approval Engineering Disease 137

Broad Institute

JULY 19, 2023

Researchers reprogram gene therapy viral vectors to bind specific protein targets By Allessandra DiCorato July 19, 2023 Breadcrumb Home Researchers reprogram gene therapy viral vectors to bind specific protein targets A new screening method zeroes in on adeno-associated viruses that enter the brain through a defined mechanism.

Therapies 98

Therapies Research Engineering Virus 98

The Pharma Data

AUGUST 9, 2021

deputy director of the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine in the FDA’s Center for Drug Evaluation and Research. “Today’s approval brings patients with Pompe disease another enzyme replacement therapy option for this rare disease.

FDA Approval 52

FDA Approval FDA Disease Treatment 52

The Pharma Data

APRIL 26, 2022

director of the FDA’s Center for Drug Evaluation and Research. Today’s approval of the first COVID-19 therapeutic for this population demonstrates the agency’s commitment to that need.”. Learn more about FDA-approved and authorized COVID-19 vaccines.

FDA Approval 52

FDA Approval FDA Treatment Vaccine 52

The Pharma Data

FEBRUARY 25, 2022

Several FDA-approved drugs – including for type 2 diabetes, hepatitis C and HIV – significantly reduce the ability of the Delta variant of SARS-CoV-2 to replicate in human cells, according to new research led by scientists at Penn State. Pfizer’s COVID-19 therapy Paxlovid, for example, targets Mpro. .

FDA Approval 52

FDA Approval FDA Molecular Biology Virus 52

KIF1A

MARCH 23, 2024

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. In this week’s article, researchers in Serbia expanded genetic testing for adult HSP patients. Want to learn more about HSP? million.

FDA Approval 105

FDA Approval Therapies FDA Disease 105

Chemical Biology and Drug Design

OCTOBER 24, 2023

However, potent FDA-approved inhibitors were identified against druggable PmrB-pocket, bypassing the mutation loci. Furthermore, PmrB having high druggability confidence (>0.99), was explored as a potential target for 1396 virtually screened FDA-approved drug candidates. pneumoniae.

FDA Approval 100

FDA Approval FDA Hospitals Research 100

Broad Institute

FEBRUARY 8, 2024

Researchers uncover genetic factors for severe Lassa fever By Allessandra DiCorato February 8, 2024 Breadcrumb Home Researchers uncover genetic factors for severe Lassa fever New findings from an international collaboration pave the way for studies of highly infectious diseases in Africa such as Ebola.

Research 81

Research Virus Hospitals Disease 81

The Pharma Data

AUGUST 31, 2021

10), as determined by an FDA-approved test, or in patients who were not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. This indication was approved under accelerated approval based on tumor response rate and duration of response.

FDA Approval 52

FDA Approval Treatment FDA Research Laboratories 52

The Pharma Data

JUNE 26, 2021

Pradaxa is the first FDA-approved blood thinning medication that children can take by mouth; the only other approved blood thinning medication for children is given by injection. Pradaxa was originally approved in 2010 to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.

FDA Approval 52

FDA Approval FDA Treatment Pharmaceuticals 52

The Pharma Data

JULY 8, 2021

KEYTRUDA has shown meaningful efficacy in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma that cannot be cured by surgery or radiation,” said Dr. Vicki Goodman, vice president, clinical research, Merck Research Laboratories. 1) as determined by an FDA-approved test.

FDA Approval 52

FDA Approval FDA Treatment Therapies 52

Chemical Biology and Drug Design

NOVEMBER 20, 2023

We employed a combined strategy involving molecular docking-based virtual screening, molecular dynamics (MD) simulation, and MM/GBSA free energy calculation on existing FDA-approved drugs. Sorafenib and glimepiride simultaneously downregulated c-Maf protein expression to induce G1 phase arrest and apoptosis in myeloma cells.

Small Molecule 100

Small Molecule Protein Expression FDA Approval FDA 100

The Pharma Data

MAY 27, 2022

Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah ® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.

FDA Approval 52

FDA Approval Therapies FDA Treatment 52

The Pharma Data

NOVEMBER 29, 2021

“The FDA’s approval of Cytalux can help enhance the ability of surgeons to identify deadly ovarian tumors that may otherwise go undetected,” said Alex Gorovets, M.D., deputy director of the Office of Specialty Medicine in the FDA’s Center for Drug Evaluation and Research. “By The FDA, an agency within the U.S.

FDA Approval 52

FDA Approval FDA Drugs Laboratories 52

The Pharma Data

OCTOBER 8, 2021

Rethymic is the first thymus tissue product approved in the U.S. “Today’s action marks the first FDA approval of a therapy to treat this very rare and devastating disease in children,” said Peter Marks, M.D., director of the FDA’s Center for Biologics Evaluation and Research.

FDA Approval 52

FDA Approval FDA Treatment Disease 52

FDA Law Blog: Drug Discovery

NOVEMBER 10, 2024

Background on the Grants Program Launched as part of the Orphan Drug Act of 1983, this program aims to encourage research and development of drugs, biologics, medical devices, and medical foods for rare diseases, defined as conditions that affect fewer than 200,000 people in the U.S. The seven awardees included six early-stage trials (e.g.,

Clinical Development 69

Clinical Development Production Clinical Trials Treatment 69

Codon

NOVEMBER 3, 2024

Even after microbiologists discovered the bacterium that causes the illness in 1882, it wasn’t until the 1920s that researchers were able to develop a vaccine for TB. Chilean research participants aged 15 to 35 who received the vaccine during a case-control study , for example, only showed a 10 percent reduced risk of pulmonary TB.

Vaccine 102

Vaccine Trials Therapies Treatment 102

The Pharma Data

NOVEMBER 21, 2021

“Today’s approval fulfills an unmet medical need for more than 10,000 children in the United States and underscores the FDA’s commitment to help make new therapies available for rare diseases,” said Theresa Kehoe, M.D., director of the Division of General Endocrinology in the FDA’s Center for Drug Evaluation and Research.

FDA Approval 52

FDA Approval FDA Regulations Drugs 52

National Institute on Drug Abuse: Nora's Blog

FEBRUARY 1, 2024

On May 14, 1974, an act of Congress established the National Institute on Drug Abuse (NIDA), and since then NIDA has led the world in funding and conducting research on drug use and addiction. The knowledge generated by NIDA research has also led to a robust and rigorous science of drug use prevention.

Science 122

Science FDA Approval Treatment Research 122

DrugBank

FEBRUARY 1, 2024

was recently profiled in the January 5, 2024 issue of Nucleic Acids Research. The article highlights the myriad ways in which we have focused on making DrugBank not just a knowledgebase, but a vital partner in your healthcare research. newsworthy, explore the full Nucleic Acids Research article. Our latest update, DrugBank 6.0,

Research 52

Research Clinical Trials FDA Approval Trials 52

The Pharma Data

FEBRUARY 25, 2022

Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction FDA approval marks a significant breakthrough for the approximately 3 million adults in the U.S. and Europe.

FDA Approval 52

FDA Approval FDA Hospitals Clinical Trials 52

The Pharma Data

AUGUST 7, 2021

For decades, we’ve made it our responsibility to research how to target the M6P receptor, the key pathway for cellular uptake of enzyme replacement therapy. Nexviazyme has been shown in clinical trials to provide patients with improvements in respiratory function and walking distance.

FDA Approval 52

FDA Approval Disease FDA Treatment 52

The Pharma Data

MAY 17, 2021

These initiatives could support insurance coverage of previously off-label uses, prevent costly new drugs from inappropriately receiving preferential regulatory treatment that is intended for drugs with no FDA-approved alternatives, and better inform clinicians by providing evidence-based information about how drugs should be used,” they noted. .

Research 52

Research FDA Approval Drugs FDA 52

The Pharma Data

SEPTEMBER 1, 2021

The FDA approval of INVEGA HAFYERA™ is based on the results of a 12-month, randomized, double-blind, non-inferiority Phase 3 global study that enrolled 702 adults (ages 18-70) living with schizophrenia from 20 countries. “For Global Therapeutic Area Head, Neuroscience, Janssen Research & Development, LLC.

FDA Approval 52

FDA Approval FDA Treatment Clinical Trials 52

Broad Institute

JULY 17, 2024

Researchers at the Broad Institute of MIT and Harvard have developed AI models that can screen the potential biological effects of drugs before they ever enter a living organism. Predictive machine learning could provide a way for researchers to "fail faster" and focus their experimental efforts on the drugs with the best bioavailability.

Pharmacokinetics 124

Pharmacokinetics Molecular Biology Drugs FDA 124

The Pharma Data

JUNE 22, 2023

FDA approval Pfizer (NYSE: PFE) announced that the U.S. FASCO, Professor and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute, University of Utah, and global lead investigator for TALAPRO-2. Pfizer’s TALZENNA® in combination with XTANDI® receives U.S.

FDA Approval 40

FDA Approval FDA Treatment Trials 40

The Pharma Data

APRIL 28, 2023

FDA approves once-weekly Sogroya® for the treatment of children living with growth hormone deficiency Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Sogroya ® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg for the treatment of children aged 2.5

FDA Approval 40

FDA Approval Treatment FDA Disease 40

DrugBank

MAY 6, 2024

A Wave of Innovations The year 2024 has already proven to be significant for the field of biologics, witnessing a notable increase in FDA approvals. In the first quarter alone, the FDA approved 9 new biologics, a substantial rise from the 5 approvals during the same period in 2023.

FDA Approval 96

FDA Approval Therapies Treatment Clinical Trials 96

Drug Target Review

MARCH 12, 2024

The study’s findings offer new insights into the biochemical language microbes use to influence distant organ systems, which could revolutionise the way researchers approach disease. The diversity and range of functions of these secondary bile acids has been greatly underappreciated by researchers until now.

Disease 111

Disease Biochemical Pharmacology FDA Approval Pharmacy 111

Drug Target Review

JANUARY 8, 2024

We are at the forefront of drug development in an area of research called cellular rejuvenation, which is an approach that has the potential to address many diseases of ageing by restoring aged and injured cells to a more youthful and resilient state. One way we are doing this at Life Biosciences is through partial epigenetic reprogramming.

Science 145

Science Disease FDA Approval Clinical Trials 145

Advarra

JANUARY 23, 2024

During the course of study conduct, most research involving human participants will require some form of planned modification or revision. This includes amendments involving changes to institutional review board (IRB)-approved protocols. Additionally, researchers must be mindful of IRB considerations as they review study changes.

Research 52

Research Therapies FDA Approval Regulations 52

Advarra

AUGUST 8, 2023

Gene therapy research is booming in the clinical setting. In this blog, we summarize the growth, risks, and regulatory requirements for gene therapy research. We also discuss how a centralized biosafety review process can benefit this type of research.

Therapies 52

Therapies Research Engineering Clinical Research 52